Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent

被引:212
作者
Valzasina, B [1 ]
Piconese, S [1 ]
Guiducci, C [1 ]
Colombo, MP [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, Immunotherapy & Gene Therapy Unit, Dept Expt Oncol, I-20133 Milan, Italy
关键词
D O I
10.1158/0008-5472.CAN-05-4217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CD25(-) and CD25(+) CD4 T-lymphocyte compartments are tightly regulated. We show here that tumors break such balance, increasing the number of CD4(+)CD25(+) T cells in draining lymph node and spleen but not contralateral node of tumor-bearing mice. Tumor injection in thymectomized and CD25-depleted mice shows that CD4(+)CD25(+) T-cell expansion occurs even in the absence of the thymus and independently from proliferation of preexisting CD25(+) T cells. These newly generated cells are bona fide regulatory T cells (T reg) in terms of Foxp3 expression and suppression of CD3-stimulated or allogeneic effector cell proliferation. Transfer of congenic Thy1.1 CD4(+)CD25(-) T cells, from mice treated or not with vinblastine, into tumor-bearing or tumor-free mice and analysis of recovered donor lymphocytes indicate that conversion is the main mechanism for acquiring the expression of CD25 and Foxp3 through a process that does not require proliferation. Although conversion of CD4(+)CD25(-) T cells for generation of T regs has been described as a natural process that maintains peripheral T-reg population, this process is used by the tumor for immune escape. The prompt recovery of T regs from monoclonal antibody-mediated CD25 depletion in tumor-bearing mice suggests attempts able to inactivate rather than deplete them when treating existing tumors.
引用
收藏
页码:4488 / 4495
页数:8
相关论文
共 56 条
[1]   Homeostasis of peripheral CD4+ T cells:: IL-2Rα and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers [J].
Almeida, ARM ;
Legrand, N ;
Papiernik, M ;
Freitas, AA .
JOURNAL OF IMMUNOLOGY, 2002, 169 (09) :4850-4860
[2]   Origin of regulatory T cells with known specificity for antigen [J].
Apostolou, I ;
Sarukhan, A ;
Klein, L ;
von Boehmer, H .
NATURE IMMUNOLOGY, 2002, 3 (08) :756-763
[3]   Chemokines and leukocyte traffic [J].
Baggiolini, M .
NATURE, 1998, 392 (6676) :565-568
[4]   Cancer and the chemokine network [J].
Balkwill, F .
NATURE REVIEWS CANCER, 2004, 4 (07) :540-550
[5]   Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER-2/neu transgenic mice [J].
Boggio, K ;
Nicoletti, G ;
Di Carlo, E ;
Cavallo, F ;
Landuzzi, L ;
Melani, C ;
Giovarelli, M ;
Rossi, I ;
Nanni, P ;
De Giovanni, C ;
Bouchard, P ;
Wolf, S ;
Modesti, A ;
Musiani, P ;
Lollini, PL ;
Colombo, MP ;
Forni, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (03) :589-596
[6]   Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].
Chen, WJ ;
Jin, WW ;
Hardegen, N ;
Lei, KJ ;
Li, L ;
Marinos, N ;
McGrady, G ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886
[7]  
COLOMBO MP, 1985, CANCER IMMUNOL IMMUN, V20, P198
[8]   CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine [J].
Comes, A ;
Rosso, O ;
Orengo, AM ;
Di Carlo, E ;
Sorrentino, C ;
Meazza, R ;
Piazza, T ;
Valzasina, B ;
Nanni, P ;
Colombo, MP ;
Ferrini, S .
JOURNAL OF IMMUNOLOGY, 2006, 176 (03) :1750-1758
[9]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[10]   CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion [J].
de Lafaille, MAC ;
Lino, AC ;
Kutchukhidze, N ;
Lafaille, JJ .
JOURNAL OF IMMUNOLOGY, 2004, 173 (12) :7259-7268